Daniel M. Kolansky, MD

Original Contribution

Cardiac Catheterization in Patients With Ascending Aortic Aneurysms: Safety, Success, and Prevalence of Coronary Artery Disease

06/02/2014

G. William Moser , CRNP;

Daniel M. Kolansky , MD;

Zachary M. Gertz , MD;

Scott A. Levitt , BSE;

Kelly C. Epps , MD;

Joseph E. Bavaria , MD;

Evaluation for coronary artery disease is recommended prior to surgery for ascending aortic aneurysms, but concerns remain regarding the use of coronary angiography in this population. We retrospectively reviewed all patients referred for...

Evaluation for coronary artery...

06/02/2014

Journal of Invasive Cardiology

Original Contribution

Patient Satisfaction is Comparable to Early Discharge versus Overnight Observation after Elective PCI (see full title below)

09/01/2009

John W. Hirshfeld Jr.;

William H. Matthai , MD;

Howard C. Herrmann , MD;

Zachary M. Gertz , MD;

Daniel M. Kolansky , MD;

Ruchira Glaser , MD, MSCE;

Robert L. Wilensky , MD;

Mark Weiner , MD;

ABSTRACT: Background. Previous investigation has suggested that early discharge after percutaneous coronary intervention (PCI) is feasible and safe, but these studies have utilized largely radial approaches or been conducted in non-U.S....

ABSTRACT: Background. Previous...

09/01/2009

Journal of Invasive Cardiology

Education Guidelines

New ACVP 2023 Educational Guidelines for Invasive Cardiovascular Technology Personnel in the Adult Cardiovascular Catheterization Laboratory

04/02/2023

Daniel M. Kolansky , MD;

Jeff Davis , RRT, RCIS, FSICP;

The ACVP has now published, with the endorsement of the SCAI, the 2023 Educational Guidelines for Invasive Cardiovascular Technology Personnel in the Adult Cardiovascular Catheterization Laboratory standards (Appendix A).

The ACVP has now published, with...

04/02/2023

Cath Lab Digest

Original Contribution

Identifying Racial, Ethnic, and Socioeconomic Inequities in the Use of Novel P2Y12 Inhibitors After Percutaneous Coronary Intervention

03/01/2022

Ashwin S. Nathan , MD;

Zhi Geng , MD, MPH;

Lauren A. Eberly , MD, MPH;

Nwamaka D. Eneanya , MD, MPH;

Jay S. Giri , MD, MPH;

Elias J. Dayoub , MD, MPP;

Daniel M. Kolansky , MD;

Sameed Ahmed M. Khatana , MD, MPH;

Sony Tuteja , PharmD, MS;

Alexander C. Fanaroff , MD, MHS;

Peter W. Groeneveld , MD, MS;

Taisei J. Kobayashi , MD;

Novel P2Y12 inhibitors prasugrel and ticagrelor were approved for patients with acute coronary syndrome (ACS) in 2009 and 2011, respectively. We assessed the association of racial, ethnic, and socioeconomic factors with initiation of and...

Novel P2Y12 inhibitors prasugrel...

03/01/2022

Journal of Invasive Cardiology

Original Contribution

Safety of Intravenous Cangrelor Administration for Antiplatelet Bridging in Hospitalized Patients: A Retrospective Study

12/01/2021

Ashwin S. Nathan , MD;

Alexander C. Fanaroff , MD, MHS;

Bryce V. Johnson , MD;

Edward R. Horton , MD;

Christopher Domenico , PharmD;

Michael A. Acker , MD;

Daniel M. Kolansky , MD;

Bryce Johnson, MD and colleagues aimed to characterize outcomes associated with cangrelor administration used in an antiplatelet bridging strategy in real-world clinical scenarios within a large academic medical system.

Bryce Johnson, MD and colleagues...

12/01/2021

Journal of Invasive Cardiology